These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

647 related items for PubMed ID: 25552670

  • 21. Sensitivity of fluorine-18-fluoromethylcholine PET/CT to prostate-specific antigen over different plasma levels: a retrospective study in a cohort of 192 patients with prostate cancer.
    Giovacchini G, Giovannini E, Borsò E, Lazzeri P, Riondato M, Leoncini R, Duce V, Conti E, Picchio M, Ciarmiello A.
    Nucl Med Commun; 2019 Mar; 40(3):258-263. PubMed ID: 30507748
    [Abstract] [Full Text] [Related]

  • 22. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
    Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L.
    J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
    [Abstract] [Full Text] [Related]

  • 23. (18)F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy.
    Kjölhede H, Ahlgren G, Almquist H, Liedberg F, Lyttkens K, Ohlsson T, Bratt O.
    World J Urol; 2015 Nov; 33(11):1749-52. PubMed ID: 25824540
    [Abstract] [Full Text] [Related]

  • 24. 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT.
    Ceci F, Castellucci P, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R, Ntreta M, Lodi F, Martorana G, Fanti S.
    Eur J Nucl Med Mol Imaging; 2014 May; 41(5):878-86. PubMed ID: 24346416
    [Abstract] [Full Text] [Related]

  • 25. A pilot study of the utility of choline PET-CT in prostate cancer biochemical relapse following radical prostatectomy.
    Tan H, Joseph D, Loh NK, McCarthy M, Leong E, Siew T, Segard T, Morandeau L, Trevenen M, Francis RJ.
    J Med Imaging Radiat Oncol; 2016 Jun; 60(3):374-81. PubMed ID: 27094471
    [Abstract] [Full Text] [Related]

  • 26. The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL.
    Mamede M, Ceci F, Castellucci P, Schiavina R, Fuccio C, Nanni C, Brunocilla E, Fantini L, Costa S, Ferretti A, Colletti PM, Rubello D, Fanti S.
    Clin Nucl Med; 2013 Sep; 38(9):e342-5. PubMed ID: 23797218
    [Abstract] [Full Text] [Related]

  • 27. Prostate-specific antigen kinetics parameters are predictive of positron emission tomography features worsening in patients with biochemical relapse after prostate cancer treatment with radical intent: Results from a longitudinal cohort study.
    Gacci M, Cai T, Siena G, Minervini A, Torshizi MF, Bartolini M, Giannì G, Saieva C, Ceroti M, Detti B, Livi L, Pupi A, Carini M.
    Scand J Urol; 2014 Jun; 48(3):259-67. PubMed ID: 24255954
    [Abstract] [Full Text] [Related]

  • 28. 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients.
    Nanni C, Schiavina R, Brunocilla E, Borghesi M, Ambrosini V, Zanoni L, Gentile G, Vagnoni V, Romagnoli D, Martorana G, Fanti S.
    Clin Genitourin Cancer; 2014 Apr; 12(2):106-10. PubMed ID: 24135632
    [Abstract] [Full Text] [Related]

  • 29. Detection rate of 18F-Choline positron emission tomography/computed tomography in patients with non-metastatic hormone sensitive and castrate resistant prostate cancer.
    Zattoni F, Artioli P, Burei M, Chiaravalloti A, Chierichetti F, Donner D, Panareo S, Rambaldi I, Schillaci O, Dal Moro F, Evangelista L.
    Q J Nucl Med Mol Imaging; 2023 Jun; 67(2):167-173. PubMed ID: 34477346
    [Abstract] [Full Text] [Related]

  • 30. Role of PET-CT with 18F-fluorocholine in biochemical recurrence after treatment of prostate cancer with curative intent.
    Puche-Sanz I, Triviño-Ibáñez E, Vázquez-Alonso F, Llamas-Elvira JM, Cózar-Olmo JM, Rodríguez-Fernández A.
    Actas Urol Esp; 2017 Sep; 41(7):437-444. PubMed ID: 28389027
    [Abstract] [Full Text] [Related]

  • 31. Role of ¹⁸F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer.
    Chondrogiannis S, Marzola MC, Ferretti A, Maffione AM, Rampin L, Grassetto G, Nanni C, Colletti PM, Rubello D.
    Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1356-64. PubMed ID: 23670521
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, Briganti A, Gianolli L, Montorsi F, Messa C.
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1106-16. PubMed ID: 20306038
    [Abstract] [Full Text] [Related]

  • 34. Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer.
    Rahbar K, Afshar-Oromieh A, Seifert R, Wagner S, Schäfers M, Bögemann M, Weckesser M.
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2055-2061. PubMed ID: 30027419
    [Abstract] [Full Text] [Related]

  • 35. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT.
    Bluemel C, Krebs M, Polat B, Linke F, Eiber M, Samnick S, Lapa C, Lassmann M, Riedmiller H, Czernin J, Rubello D, Bley T, Kropf S, Wester HJ, Buck AK, Herrmann K.
    Clin Nucl Med; 2016 Jul; 41(7):515-21. PubMed ID: 26975008
    [Abstract] [Full Text] [Related]

  • 36. [Biochemical recurrence after curative treatment for localized prostate cancer: Performance of choline PET/CT in the assessment of local recurrence].
    Poncet D, Arnoux V, Descotes JL, Rambeaud JJ, Verry C, Terrier N, Boillot B, Dubreuil J, Lanchon C, Carnicelli D, Fiard G, Long JA.
    Prog Urol; 2015 May; 25(6):325-30. PubMed ID: 25748788
    [Abstract] [Full Text] [Related]

  • 37. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?
    Heinisch M, Dirisamer A, Loidl W, Stoiber F, Gruy B, Haim S, Langsteger W.
    Mol Imaging Biol; 2006 May; 8(1):43-8. PubMed ID: 16315004
    [Abstract] [Full Text] [Related]

  • 38. 18F-choline PET/computed tomography and clinical parameters in the detection of significant prostate cancer in patients with increased prostate-specific antigen levels and previous negative biopsies.
    Jiménez Londoño GA, García Vicente AM, Noriega Álvarez E, Pena Pardo FJ, Amo-Salas M, López Guerrero MA, Fúnez Mayorga F, Soriano Castrejón ÁM.
    Nucl Med Commun; 2020 Jul; 41(7):674-681. PubMed ID: 32404644
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy.
    Giovacchini G, Picchio M, Garcia-Parra R, Briganti A, Abdollah F, Gianolli L, Schindler C, Montorsi F, Messa C, Fazio F.
    J Nucl Med; 2014 Feb; 55(2):233-41. PubMed ID: 24408897
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.